Titan Pharmaceuticals, Inc.

NasdaqCM:TTNP Stock Report

Market Cap: US$4.2m

Titan Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TTNP?
Owner TypeNumber of SharesOwnership Percentage
Institutions26,6832.92%
Individual Insiders340,79937.3%
General Public546,75259.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 22 shareholders own 40.2% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20.5%
Choon Hau Choong
187,399US$865.8k-1.42%no data
16.4%
Jeffrey Chung
150,087US$693.4k0%no data
1.31%
Citadel Advisors LLC
11,961US$55.3k0%no data
0.86%
Geode Capital Management, LLC
7,872US$36.4k23.6%no data
0.45%
The Vanguard Group, Inc.
4,103US$19.0k0%no data
0.36%
Avraham Ben-Tzvi
3,313US$15.3k0%no data
0.28%
UBS Asset Management AG
2,594US$12.0k-2.74%no data
0.0096%
CoreCap Advisors, LLC
88US$406.70%no data
0.002%
Bank of America Corporation, Asset Management Arm
18US$83.25.88%no data
0.0016%
Osaic Wealth, Inc. , Asset Management Arm
15US$69.3114%no data
0.0013%
Group One Trading LP, Asset Management Arm
12US$55.30%no data
0.00066%
BlackRock, Inc.
6US$27.90%no data
0.00044%
Morgan Stanley, Investment Banking and Brokerage Investments
4US$18.633.3%no data
0.00022%
Global Wealth Strategies And Associates, LLC
2US$9.30%no data
0.00011%
St. Germain Investment Management, Inc.
1US$4.60%no data
0.00011%
Westside Investment Management, LLC
1US$4.60%no data
0.00011%
SBI Holdings Inc., Asset Management Arm
1US$4.60%no data
0.00011%
Wells Fargo & Company, Securities and Brokerage Investments
1US$4.60%no data
0.00011%
Caldwell Securities Incorporated, Asset Management Arm
1US$4.60%no data
0.00011%
Cape Investment Advisory, Inc.
1US$4.60%no data
0.00011%
Nemes Rush Group, LLC
1US$4.60%no data
0.00011%
Ransom Advisory, LTD
1US$4.60%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 00:21
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Titan Pharmaceuticals, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Benjamin HaynorAlliance Global Partners
Michael HigginsBrinson Patrick Securities Corporation
Jason McCarthyMaxim Group